G43.0 G43.1
Conditions
Interventions
Group 1: Investigate Patients with cronic or episodic migraine by using the CEQ, SF12, GASE, HIT6 and DASS for six months prior to the start of a new migraine prophylaxis or an add on prophylaxis
Sponsors
Klinische NeurowissenschaftenUniversitätsklinikum EssenKlinik für Neurologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with episodic or chronic migraine starting a new medical prophylaxis comprising amitriptyline, beta blockers, topiramate, valproic acid, magnesium, flunarizine or onabotulinumtoxinA (new prophylaxis or add on)
Exclusion criteria
Exclusion criteria: pregnancy or breast-feeding missing language skills
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of headache days over the course of 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of migraine days, pain intensity, pain duration, quality of life, side effects, impairment related to headache, depression, anxiety and stress over a period of 6 months. Differences between responders and non-responders. Differences between patients with and without prior experiences with pharmacological prophylaxis. Influence expectation (CEQ-expectancy) and genetic predispositions (COMT) on all endpoints will be investigated. | — |
Countries
Germany
Contacts
Public ContactTobias Berding
Uniklinikum Essen - Klinik für Neurologie
Outcome results
None listed